Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.80), $0.42 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $157 million versus the consensus estimate of $130.76 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2025 EPS of $875.00-$900.00, versus the consensus of $866.50.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.